HemaSphere (Jun 2022)
P1047: REAL-WORLD SAFETY OF RUXOLITINIB IN PATIENTS WITH INTERMEDIATE OR HIGH RISK OF PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS IN CHINA
- Z. Xu,
- M. Duan,
- Q. Jiang,
- Q. Leng,
- N. Xu,
- Y. Zhang,
- C. Zhao,
- W. Wu,
- Q. Zhang,
- J. Fu,
- J. Zhang,
- R. Fu,
- Z. Yan,
- J. Zhang,
- C. Lin,
- G. Ouyang,
- Z. Wang,
- L. Ma,
- H. Hao,
- X. Li,
- S. Ran,
- Y. Chen,
- T. Li,
- Z. Xiao
Affiliations
- Z. Xu
- 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
- M. Duan
- 2 Peking Union Medical College Hospital
- Q. Jiang
- 3 Peking University People’s Hospital, Beijing
- Q. Leng
- 4 Anshan Central Hospital, Liaoning
- N. Xu
- 5 Nanfang Hospital, Southern Medical University, Guangdong
- Y. Zhang
- 6 Henan Provincial People’s Hospital, Henan
- C. Zhao
- 7 Affiliated Hospital of Qingdao University, Shandong
- W. Wu
- 8 Ruijin Hospital, Shanghai Jiao Tong University, Shanghai
- Q. Zhang
- 9 Gansu Provincial People’s Hospital, Gansu
- J. Fu
- 10 Shaoxing People’s Hospital, Zhejiang
- J. Zhang
- 11 The Second Hospital of Hebei Medical University, Hebei
- R. Fu
- 12 Tianjin Medical University General Hospital, Tianjin
- Z. Yan
- 13 North China University of Technology Affiliated Hospital, Hebei
- J. Zhang
- 14 Nanchang University Affiliated Ganzhou Hospital, Jiangxi
- C. Lin
- 15 Zhangzhou Affiliated Hospital of Fujian Medical University, Fujian
- G. Ouyang
- 16 Ningbo First Hospital, Zhejiang
- Z. Wang
- 17 Wuxi Second People’s Hospital, Jiangsu
- L. Ma
- 18 Sun Yat Sen Memorial Hospital of Sun Yat Sen University, Guangdong
- H. Hao
- 19 Hebei General Hospital, Hebei
- X. Li
- 20 Affiliated Hospital of Southwest Medical University, Sichuan
- S. Ran
- 21 Beijing Novartis Pharma Co., Ltd, Beijing
- Y. Chen
- 22 China Novartis Institutes For Biomedical Research Co., Ltd
- T. Li
- 23 China Novartis Institutes For Biomedical Research Co., Ltd., Shanghai, China
- Z. Xiao
- 1 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin
- DOI
- https://doi.org/10.1097/01.HS9.0000847056.62279.a3
- Journal volume & issue
-
Vol. 6
pp. 937 – 938
Abstract
No abstracts available.